| Document Date: 2014-08-12 13:02:45
Open Document File Size: 111,95 KBShare Result on Facebook
City Washington / DC / New York / Chicago / / Company Pfizer Inc. / / Event FDA Phase / Product Issues / Person Communication and Meetings / / Facility American College / / IndustryTerm treatment of psoriasis / treatment of rheumatic diseases / / MedicalCondition disease / active rheumatoid arthritis receiving stable-dose methotrexate / rheumatic diseases / Rheumatoid arthritis / Allergy / tumor necrosis / severely active rheumatoid arthritis / tumor necrosis factor / active ulcerative colitis / psoriasis / active rheumatoid arthritis / inflammatory condition / / MedicalTreatment immunosuppression / kidney transplant / / Organization Center for Drug Evaluation & Research / Food and Drug Administration / Arthritis Advisory Committee / American College of Rheumatology / / Person Care Res (Hoboken) / Ann Rheum / / / Position physician / / Product Humira / Orencia / Kineret / leflunomide / Enbrel / Rituxan / cyclosporine / sulfasalazine / Remicade / azathioprine / Janus / CP-690 / Xeljanz® / response / / ProvinceOrState Illinois / / Technology gene expression / pdf / / URL http /
SocialTag |
Xeljanz® (tofacitinib tablets – Pfizer) To Initiate a Coverage Review, Call[removed]OVERVIEW Xeljanz is an inhibitor of the Janus kinases (JAK) pathways approved for the treatment of adults with moderately to s